Clinical Imaging最新文献

英文中文

Filling the pipeline or repairing the system? A deep reflection on recruitment strategies for nuclear medicine 填充管道还是修复系统？对核医学人才招聘策略的深刻思考。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-10-06 DOI: 10.1016/j.clinimag.2025.110629

Hongnan Ye

引用次数: 0

Response to the letter to the editor regarding ‘Strategies to enhance recruitment in nuclear medicine: A path forward’ 对致编辑的关于“加强核医学招聘的战略：前进的道路”的信的回应。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-10-06 DOI: 10.1016/j.clinimag.2025.110630

Shinji Rho , Kevin P. Fialkowski , Samantha G. Harrington , Bashar Kako , Merissa N. Zeman , Hyewon Hyun , Matt Robertson , Thomas S.C. Ng

引用次数: 0

Breast cryoablation for management of benign fibroadenomas: A systematic review of the literature 乳腺冷冻消融术治疗良性纤维腺瘤：文献系统综述。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-30 DOI: 10.1016/j.clinimag.2025.110632

Yash Ramgopal , Katerina Dodelzon , Kristen Coffey , Nicole A. Lamparello

Purpose

Breast fibroadenomas are among the most common benign breast lesions in women. While surgical excision remains the standard treatment when intervention is indicated or desired, minimally invasive cryoablation has emerged as a promising alternative. This study systematically evaluates the safety and efficacy of breast cryoablation for fibroadenomas.

Methods

A systematic literature review was conducted in accordance with PRISMA guidelines across three major databases to identify clinical studies evaluating cryoablation for fibroadenomas. Eligible studies were analyzed for patient demographics, lesion characteristics, treatment outcomes, and complications. Risk of bias was assessed using the ROBINS-I tool.

Results

Of the 123 studies identified in preliminary review, 6 were eligible for inclusion. A total of 190 fibroadenomas were studied. There was a low overall risk of bias using the ROBINS-I tool. Mean reduction in volume of fibroadenoma, a measure of cryoablation efficacy, ranged from 78.2 % to 98 %. Multiple studies reported a three-fold decrease in fibroadenoma palpability post-cryoablation. The pooled minor complication rate from cryoablation of fibroadenomas was found to be 6.9 % (95 % CI: 3.1 %–14.8 %). Minor complications included edema, tenderness, and cosmetic changes. No major complications were noted.

Conclusion

Cryoablation is a safe and effective minimally invasive treatment option for breast fibroadenomas, offering durable lesion reduction, favorable cosmetic outcomes, and a low complication rate. While current evidence is encouraging, larger prospective trials with standardized outcomes measures will validate these findings and define the long-term role of cryoablation in benign breast disease management.

目的：乳腺纤维腺瘤是女性乳腺最常见的良性病变之一。虽然手术切除仍然是指征或需要干预时的标准治疗方法，但微创冷冻消融已成为一种有希望的替代方法。本研究系统评价冷冻消融治疗乳腺纤维腺瘤的安全性和有效性。方法：根据PRISMA指南对三个主要数据库进行系统的文献综述，以确定评估纤维腺瘤冷冻消融的临床研究。对符合条件的研究进行患者人口统计学、病变特征、治疗结果和并发症的分析。使用ROBINS-I工具评估偏倚风险。结果：在初步审查中确定的123项研究中，有6项符合纳入条件。我们共研究了190例纤维腺瘤。使用ROBINS-I工具的总体偏倚风险较低。纤维腺瘤体积的平均减少，冷冻消融效果的衡量，范围从78.2%到98%。多项研究报道，冷冻消融后纤维腺瘤的触诊率降低了三倍。纤维腺瘤冷冻消融的合并轻微并发症发生率为6.9% （95% CI: 3.1% - 14.8%）。轻微并发症包括水肿、压痛和外观改变。无重大并发症。结论：冷冻消融术是一种安全有效的乳腺纤维腺瘤的微创治疗方法，具有持久的病变缩小、良好的美容效果和低并发症发生率。虽然目前的证据令人鼓舞，但采用标准化结果测量的更大规模前瞻性试验将验证这些发现，并确定冷冻消融在良性乳腺疾病治疗中的长期作用。

{"title":"Breast cryoablation for management of benign fibroadenomas: A systematic review of the literature","authors":"Yash Ramgopal , Katerina Dodelzon , Kristen Coffey , Nicole A. Lamparello","doi":"10.1016/j.clinimag.2025.110632","DOIUrl":"10.1016/j.clinimag.2025.110632","url":null,"abstract":"<div><h3>Purpose</h3><div>Breast fibroadenomas are among the most common benign breast lesions in women. While surgical excision remains the standard treatment when intervention is indicated or desired, minimally invasive cryoablation has emerged as a promising alternative. This study systematically evaluates the safety and efficacy of breast cryoablation for fibroadenomas.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted in accordance with PRISMA guidelines across three major databases to identify clinical studies evaluating cryoablation for fibroadenomas. Eligible studies were analyzed for patient demographics, lesion characteristics, treatment outcomes, and complications. Risk of bias was assessed using the ROBINS-I tool.</div></div><div><h3>Results</h3><div>Of the 123 studies identified in preliminary review, 6 were eligible for inclusion. A total of 190 fibroadenomas were studied. There was a low overall risk of bias using the ROBINS-I tool. Mean reduction in volume of fibroadenoma, a measure of cryoablation efficacy, ranged from 78.2 % to 98 %. Multiple studies reported a three-fold decrease in fibroadenoma palpability post-cryoablation. The pooled minor complication rate from cryoablation of fibroadenomas was found to be 6.9 % (95 % CI: 3.1 %–14.8 %). Minor complications included edema, tenderness, and cosmetic changes. No major complications were noted.</div></div><div><h3>Conclusion</h3><div>Cryoablation is a safe and effective minimally invasive treatment option for breast fibroadenomas, offering durable lesion reduction, favorable cosmetic outcomes, and a low complication rate. While current evidence is encouraging, larger prospective trials with standardized outcomes measures will validate these findings and define the long-term role of cryoablation in benign breast disease management.</div></div>","PeriodicalId":50680,"journal":{"name":"Clinical Imaging","volume":"127 ","pages":"Article 110632"},"PeriodicalIF":1.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducing "Private Practice Corner" “私人执业角”简介

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-30 DOI: 10.1016/j.clinimag.2025.110631

Narmadan A. Kumarasamy , Jennifer Kemp

引用次数: 0

Imaging of central lymphatics in children with Both Trisomy 21 and congenital heart disease 小儿21三体合并先天性心脏病的中央淋巴管影像学研究。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-26 DOI: 10.1016/j.clinimag.2025.110627

Stephanie El Omeiri , Karen I. Ramirez-Suarez , Joseph Stern , Hansel J. Otero , Yoav Dori , David M. Biko , Jordan B. Rapp , Fernando Escobar , Aaron Dewitt , Ganesh Krishnamurthy , Abhay Srinivasan , Christopher L. Smith

Objective

To describe the lymphatic imaging findings in patients with both Trisomy 21 and congenital heart disease and to depict the most common central lymphatic abnormalities in these patients.

Materials and methods

We conducted a single-center retrospective review of patients with a confirmed history of Trisomy 21 and congenital heart disease who presented for lymphatic imaging over a 7-year period. Clinical history and outcomes were extracted from the medical records. Lymphatic distribution and flow were evaluated by two pediatric radiologists from dynamic contrast-enhanced MR lymphangiography studies, which included T2-weighted and dynamic contrast-enhanced T1-weighted images, conventional lymphangiography studies were also evaluated.

Results

We identified 16 patients (12 male): 8 infants, 6 children, and 2 adults. 12 patients had cardiac surgery including Fontan (n = 5), hemi-Fontan (n = 1), Glenn (n = 1), and other cardiac surgeries (n = 5). Presenting symptoms included chylothorax, plastic bronchitis, chylous ascites, protein losing enteropathy, pericardial effusion, lymphedema, and anasarca. Two patients died (12 %) by the time of data collection. T2-weighted MR imaging demonstrated lymphatic edema in all patients. T1-weighted dynamic imaging revealed abnormal pulmonary and/or mesenteric lymphatic perfusion in 15 patients (88 %) across intranodal, intrahepatic, and intramesenteric access types. The thoracic duct was tortuous and/or dilated in most cases. Conventional lymphangiography confirmed thoracic duct obstruction.

Conclusion

This is a descriptive study of central lymphatic diseases in patients with Trisomy 21, congenital heart disease and clinical evidence of lymphatic dysfunction. Common findings in these patients include retrograde dermal lymphatic flow, pulmonary and mesenteric lymphatic perfusion as well as the presence of a dilated and tortuous duct.

目的：描述21三体合并先天性心脏病患者的淋巴影像学表现，并描述这些患者中最常见的中枢淋巴异常。材料和方法：我们对证实有21三体病史和先天性心脏病的患者进行了一项单中心回顾性研究，这些患者在7年内进行了淋巴影像学检查。从医疗记录中提取临床病史和结果。两名儿科放射科医生通过动态对比增强MR淋巴管造影研究（包括t2加权和动态对比增强t1加权图像）评估了淋巴分布和流量，也评估了常规淋巴管造影研究。结果：我们确定了16例患者（男性12例）：8例婴儿，6例儿童，2例成人。12例患者行心脏手术，包括Fontan （n = 5）、半Fontan （n = 1）、Glenn （n = 1）和其他心脏手术（n = 5）。其症状包括乳糜胸、塑性支气管炎、乳糜腹水、蛋白质丢失性肠病、心包积液、淋巴水肿和腹水。截至数据收集时，2例患者死亡（12%）。t2加权磁共振成像显示所有患者淋巴水肿。t1加权动态成像显示15例（88%）患者的肺和/或肠系膜淋巴灌注异常，跨越结内、肝内和肠内通路类型。大多数病例的胸导管迂曲和/或扩张。常规淋巴管造影证实胸导管阻塞。结论：这是一项关于21三体患者中枢性淋巴疾病、先天性心脏病和淋巴功能障碍临床证据的描述性研究。这些患者的常见表现包括逆行性皮肤淋巴流，肺部和肠系膜淋巴灌注以及导管扩张和弯曲的存在。

{"title":"Imaging of central lymphatics in children with Both Trisomy 21 and congenital heart disease","authors":"Stephanie El Omeiri , Karen I. Ramirez-Suarez , Joseph Stern , Hansel J. Otero , Yoav Dori , David M. Biko , Jordan B. Rapp , Fernando Escobar , Aaron Dewitt , Ganesh Krishnamurthy , Abhay Srinivasan , Christopher L. Smith","doi":"10.1016/j.clinimag.2025.110627","DOIUrl":"10.1016/j.clinimag.2025.110627","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the lymphatic imaging findings in patients with both Trisomy 21 and congenital heart disease and to depict the most common central lymphatic abnormalities in these patients.</div></div><div><h3>Materials and methods</h3><div>We conducted a single-center retrospective review of patients with a confirmed history of Trisomy 21 and congenital heart disease who presented for lymphatic imaging over a 7-year period. Clinical history and outcomes were extracted from the medical records. Lymphatic distribution and flow were evaluated by two pediatric radiologists from dynamic contrast-enhanced MR lymphangiography studies, which included T2-weighted and dynamic contrast-enhanced T1-weighted images, conventional lymphangiography studies were also evaluated.</div></div><div><h3>Results</h3><div>We identified 16 patients (12 male): 8 infants, 6 children, and 2 adults. 12 patients had cardiac surgery including Fontan (<em>n</em> = 5), hemi-Fontan (<em>n</em> = 1), Glenn (n = 1), and other cardiac surgeries (n = 5). Presenting symptoms included chylothorax, plastic bronchitis, chylous ascites, protein losing enteropathy, pericardial effusion, lymphedema, and anasarca. Two patients died (12 %) by the time of data collection. T2-weighted MR imaging demonstrated lymphatic edema in all patients. T1-weighted dynamic imaging revealed abnormal pulmonary and/or mesenteric lymphatic perfusion in 15 patients (88 %) across intranodal, intrahepatic, and intramesenteric access types. The thoracic duct was tortuous and/or dilated in most cases. Conventional lymphangiography confirmed thoracic duct obstruction.</div></div><div><h3>Conclusion</h3><div>This is a descriptive study of central lymphatic diseases in patients with Trisomy 21, congenital heart disease and clinical evidence of lymphatic dysfunction. Common findings in these patients include retrograde dermal lymphatic flow, pulmonary and mesenteric lymphatic perfusion as well as the presence of a dilated and tortuous duct.</div></div>","PeriodicalId":50680,"journal":{"name":"Clinical Imaging","volume":"127 ","pages":"Article 110627"},"PeriodicalIF":1.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality improvement initiative to increase radiologist reporting of the Alberta stroke program early CT score (ASPECTS) 提高阿尔伯塔中风项目早期CT评分的放射科医生报告质量的倡议（方面）。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-25 DOI: 10.1016/j.clinimag.2025.110628

Christine Lamoureux , Shwan Kim , Patrick McGaughey , Edward Callaway , Zeljko Velichkovich , Joshua Morais , Sloan Miller

引用次数: 0

ChatGPT in radiology exams: Promise, pitfalls, and pathways forward 放射学考试中的ChatGPT：前景、陷阱和前进的道路。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-19 DOI: 10.1016/j.clinimag.2025.110624

Eren Çamur , Turay Cesur , Yasin Celal Güneş

引用次数: 0

Re: Re: Evaluating ChatGPT's performance across radiology subspecialties: A meta-analysis of board examination accuracy and variability 评估ChatGPT在放射学亚专科的表现：委员会检查准确性和可变性的荟萃分析。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-19 DOI: 10.1016/j.clinimag.2025.110623

Dan Nguyen , Arash Bedayat

引用次数: 0

Multiparametric MRI and clinical factors for predicting early recurrence of breast cancer after modified radical mastectomy 多参数MRI及临床因素预测乳腺癌改良根治术后早期复发

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-18 DOI: 10.1016/j.clinimag.2025.110625

Quan-hua Chen , Chongze Yang , Lan-hui Qin , Yan-ling Liang , Wei-wei Jiang , Jin-yuan Liao

Objective

To determine whether preoperative multiparametric MRI features and clinicopathological factors can predict early recurrence in breast cancer patients following modified radical mastectomy (MRM).

Materials and methods

This retrospective study included 132 patients who underwent MRM at two hospitals from January 2012 to December 2022. Patients were classified into early recurrence (disease-free survival ≤3 years, n = 86) or late recurrence (>3 years, n = 46). We collected preoperative MRI features (tumor size, morphology, enhancement patterns, apparent diffusion coefficient (ADC) values, early enhancement rate, time-signal intensity curves) and clinical/pathological factors (age, menstruation status, neoadjuvant chemotherapy, T/N/TNM stage, tumor grade, axillary nodal involvement, vascular/nerve/nipple/skin invasion, ER, PR, HER-2, Ki-67, molecular subtype, and adjuvant therapies). Univariate and multivariate analyses (binary logistic and Cox regression) identified independent predictors of early recurrence and their impact on disease-free survival. Predictive accuracy was assessed by ROC curves.

Results

Significant factors associated with early recurrence (P < 0.05) included tumor size, ADC value, early enhancement rate, axillary lymph node metastasis, T and TNM stage, vascular invasion, ER, PR, HER-2, molecular subtype, and endocrine therapy. Multivariate analysis identified early enhancement rate, lower ADC value, and larger tumor diameter as independent predictors (AUC = 0.899). These MRI factors, together with lack of endocrine therapy, also independently influenced disease-free survival.

Conclusion

Preoperative multiparametric MRI features, especially early enhancement rate and tumor size, combined with endocrine therapy status, can predict early recurrence, enhancing prognosis for patients undergoing MRM.

目的探讨术前多参数MRI特征及临床病理因素对乳腺癌改良根治术（MRM）术后早期复发的预测价值。材料和方法本回顾性研究包括2012年1月至2022年12月在两家医院接受磁共振成像的132例患者。患者分为早期复发（无病生存期≤3年，n = 86）和晚期复发（≤3年，n = 46）。我们收集了术前MRI特征（肿瘤大小、形态、增强模式、表观扩散系数（ADC）值、早期增强率、时间信号强度曲线）和临床/病理因素（年龄、月经状况、新辅助化疗、T/N/TNM分期、肿瘤分级、腋窝淋巴结累及、血管/神经/乳头/皮肤侵犯、ER、PR、HER-2、Ki-67、分子亚型和辅助治疗）。单因素和多因素分析（二元逻辑和Cox回归）确定了早期复发的独立预测因素及其对无病生存的影响。以ROC曲线评估预测准确度。结果肿瘤大小、ADC值、早期增强率、腋窝淋巴结转移、T、TNM分期、血管侵犯、ER、PR、HER-2、分子亚型、内分泌治疗与早期复发相关（P < 0.05）。多因素分析发现早期增强率、较低的ADC值和较大的肿瘤直径是独立预测因子（AUC = 0.899）。这些MRI因素，加上缺乏内分泌治疗，也独立影响无病生存。结论术前MRI多参数特征，尤其是早期增强率和肿瘤大小，结合内分泌治疗情况，可预测MRM患者早期复发，提高预后。

{"title":"Multiparametric MRI and clinical factors for predicting early recurrence of breast cancer after modified radical mastectomy","authors":"Quan-hua Chen , Chongze Yang , Lan-hui Qin , Yan-ling Liang , Wei-wei Jiang , Jin-yuan Liao","doi":"10.1016/j.clinimag.2025.110625","DOIUrl":"10.1016/j.clinimag.2025.110625","url":null,"abstract":"<div><h3>Objective</h3><div>To determine whether preoperative multiparametric MRI features and clinicopathological factors can predict early recurrence in breast cancer patients following modified radical mastectomy (MRM).</div></div><div><h3>Materials and methods</h3><div>This retrospective study included 132 patients who underwent MRM at two hospitals from January 2012 to December 2022. Patients were classified into early recurrence (disease-free survival ≤3 years, <em>n</em> = 86) or late recurrence (>3 years, <em>n</em> = 46). We collected preoperative MRI features (tumor size, morphology, enhancement patterns, apparent diffusion coefficient (ADC) values, early enhancement rate, time-signal intensity curves) and clinical/pathological factors (age, menstruation status, neoadjuvant chemotherapy, T/N/TNM stage, tumor grade, axillary nodal involvement, vascular/nerve/nipple/skin invasion, ER, PR, HER-2, Ki-67, molecular subtype, and adjuvant therapies). Univariate and multivariate analyses (binary logistic and Cox regression) identified independent predictors of early recurrence and their impact on disease-free survival. Predictive accuracy was assessed by ROC curves.</div></div><div><h3>Results</h3><div>Significant factors associated with early recurrence (<em>P</em> < 0.05) included tumor size, ADC value, early enhancement rate, axillary lymph node metastasis, T and TNM stage, vascular invasion, ER, PR, HER-2, molecular subtype, and endocrine therapy. Multivariate analysis identified early enhancement rate, lower ADC value, and larger tumor diameter as independent predictors (AUC = 0.899). These MRI factors, together with lack of endocrine therapy, also independently influenced disease-free survival.</div></div><div><h3>Conclusion</h3><div>Preoperative multiparametric MRI features, especially early enhancement rate and tumor size, combined with endocrine therapy status, can predict early recurrence, enhancing prognosis for patients undergoing MRM.</div></div>","PeriodicalId":50680,"journal":{"name":"Clinical Imaging","volume":"127 ","pages":"Article 110625"},"PeriodicalIF":1.5,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Critical radiology results in thoracic imaging; categorization by urgency and clinical outcome” [Clin Imaging volume 126 (October 2025)/110594] “胸部成像中的关键放射学结果；按急迫性和临床结果分类”[临床影像学卷126（2025年10月）/110594]。

IF 1.5 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Imaging

Pub Date : 2025-09-15 DOI: 10.1016/j.clinimag.2025.110619

Ji Young Jeon , So Hyun Park , Hee Young Lee

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical Imaging

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀